Upstream therapy, what's new?


Authors: R. Lábrová
Authors‘ workplace: Interní kardiologická klinika LF MU a FN Brno
Published in: Kardiol Rev Int Med 2017, 19(4): 231-236

Overview

Atrial fibrillation (AF) is the most common arrhythmia and is associated with high morbidity and mortality and poor quality of life. Remodelling of the atrial substrate begins long before the first episode of AF and continues to progress. AF can maintain and further deepen most of the mechanisms of remodelling and hypercoagulability, which makes it progressive in itself. Upstream therapy reduces the progression of remodelling or induces positive remodelling of the atrium, thus preventing AF or improving sinus rhythm maintenance. In patients without history of AF who have heart failure with reduced left ventricular function and/or have hypertension or possibly left ventricular hypertrophy are indicated for the primary prevention of AF by the use of renin-angiotensin-aldosterone system blockers (ACE-I or sartans). Treatment with RAAS antagonists is indicated for these diagnoses as well as for secondary prevention. Patients with recurrent AF in antiarrhythmic therapy undergoing electrical cardioversion may be pre-treated with ACE-I or sartans. In patients without structural heart disease, this ACE-I or sartan treatment is not indicated in primary or secondary prevention. Based on the results of the RACE 3 study, upstream therapy in secondary prevention in patients undergoing cardioversion, maximum tolerated doses of RAAS blockers, statins, weight reduction diet, rehabilitation and psychological education for patient collaboration are recommended. Accentuated upstream therapy leads to a sustained sinus rhythm after 1 year of follow-up in 75% of patients as compared to 63% achieved with conventional therapy.

Key words:
atrial remodelling – atrial fibrillation – rhythm control – upstream therapy – renin-angiotensin-aldosterone system blockers – angiotension-converting enzyme inhibitors – angiotensin receptor blockers – primary and secondary prevention


Sources

1. Benjamin EJ, Levy D. Independent risk factors for atrial fibril­lation in a population-based kohort. The Framingham Heart Study. JAMA 1994; 27(11): 840– 844.

2. Lábrová R. Epidemilogie fibrilace síní. Kardiofórum 2007; 5(1): 6– 10.

3. McGovern PG, Jacobs DR Jr, Shahar E et al. Trends in acute coronary heart dis­ease mortality, morbidity, and medical care from 1985 through 1997: the Min­nesota Heart Survey. Circulation 2001; 104(1): 19– 24.

4. Anders­son T, Magnuson A, Bryngels­son IL et al. Al­l-cause mortality in 272,186 patients hospitalized with incident atrial fibril­lation 1995-2008: a Swedish nationwide long-term case-control study. Eur Heart J 2013; 34(14): 1061– 1067. doi: 10.1093/ eurheartj/ ehs469.

5. Bonita R, Solomon N, Broad JB. Prevalence of stroke and stroke-relevant disability. Stroke 1997; 28(10): 1898– 1902.

6. Lábrová R, Špinar J. Srdeční selhání a fibrilace síní. Cor Vasa 2008; 50(10): 358– 392.

7. Olesen MS, Nielsen MW, Haunso S et al. Atrial fibril­lation: the role ofcom­mon and rare genetic variants. Eur J Hum Genet 2014; 22(3): 297– 306. doi: 10.1038/ ejhg.2013.139.

8. Tada H, Shif­fman D, Smith JG et al. Twelve-single nucleotide polymorphism genetic risk score identifies individuals at increased riskfor future atrial fibril­lation and stroke. Stroke 2014; 45(10): 2856– 2862.

9. Savelieva I, Camm AJ. Is there any hope for angiotensin-convert­­ing enzyme inhibitors in atrial fibril­lation? Am Heart J 2007; 154(3): 403– 406. doi: 10.1016/ j.ahj.2007.05.008.

10. Kirchhof P, Benus­si S, Kotecha D et al. 2016 ESC Guidelines for the management of atrial fibril­lation developed in col­laboration with EACTS, The Task Force for the management of atrial fibril­lation of the European Society of Cardiology (ESC), Developed with the special contribution of the European Heart, Rhythm As­sociation (EHRA) of the ESC, Endorsed by the European Stroke Organisation (ESO). Eur Heart J 2016; 37(38): 2893– 2962. doi: 10.1093/ eurheartj/ ehw210.

11. Čihák R, Haman L, Táborský M. 2016 ESC Guide­lines for the management of atrial fibril­lation developed in col­laboration with EACTS. Sum­mary of the document prepared by the Czech Society of Cardiology. Cor Vasa 2016; 58: e636– e683. Dostupné na: http:/ / www.sciencedirect.com/ science/ article/ pii/ S0010865016301047.

12. Dobrev D, Friedrich A, Voigt N et al. The G protein-gated potas­sium cur­rent I (K,ACh) is constitutively active in patients with chronic atrial fibril­lation. Circulation 2005; 112(24): 3697– 3706. doi: 10.1161/ CIRCULATIONAHA.105.575332.

13. Van Wagoner DR, Pond AL, Lamorgese M et al. Atrial L-type Ca2+ cur­rents and human atrial fibril­lation. Circ Res 1999; 85(5): 428– 436.

14. Bosch RF, Scherer CR, Rub NL et al. Molecular mechanisms of early electrical remodeling: transcriptional downregulation of ion chan­nel subunits deduces I (Ca,L) an I(to) in rapid atrial pac­­ing in rabbits. J Am Coll Cardiol 2003; 41(5): 858– 869.

15. Madrid AH, Escobar C, Rebol­lo JM et al. Angiotensin receptor blocker as adjunctive ther­apy for rhythm control in atrial fibril­lation: results of the irbesartan-amiodarone trial. Card Electrophysiol Rev 2003; 7(3): 243– 246.

16. Lim HS, Wil­loughby SR, Schultz C et al. Ef­fect of atrial fibril­lation on atrial thrombogenesis in humans: impact of rate and rhythm. J Am Coll Cardiol 2013; 61(8): 852– 860. doi: 10.1016/ j.jacc.2012.11.046.

17. Hijazi Z, Oldgren J, Siegbahn A et al. Biomarkers in atrial fibril­lation: a clinical review. Eur Heart J 2013; 34(20): 1475– 1480. doi: 10.1093/ eurheartj/ eht024.

18. Lábrová R. Fibrilace síni v době katetrové ablace. Vnitr Lek 2010; 56(8): 871– 879.

19. Freestone B, Beevers DG, Lip GY. The renin-angiotensin-aldosterone system in atrial fibril­lation: a netherapeutic target? J Hum Hypertens 2004; 18(7): 461– 465. doi: 10.1038/ sj.jhh.1001694.

20. Das UN. Is angiotensin-II an endogenous proinflam­matory molecule? Med Sci Monit 2005; 11(5): 155– 162.

21. Healey JS, Baranchuk A, Crystal E et al. Prevention of atrial fibril­lation with angiotensin-convert­­ing enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005; 45:1832– 1839.

22. Jibrini MB, Molnar J, Arora RR. Prevention of atrial fibril­lation by way of abrogation of the renin-angiotensin system: a systematic review and meta-analysis. Am J Therb 2008; 15(1): 36– 43. doi: 10.1097/ MJT.0b013e31804beb59.

23. Huang G, Xu JB, Liu JX et al. Angiotensin-convert­­ing enzyme inhibitors and angiotensin receptor blockers decrease the incidence of atrial fibril­lation: a meta-analysis. Eur J Clin Invest. 2011; 41(7): 719– 733. doi: 10.1111/ j.1365-2362.2010.02460.x.

24. Han M, Zhang Y, Sun S et al. Renin-angiotensin system inhibitors prevent the recur­rence of atrial fibril­lation: a meta-analysis of randomized control­led trials. J Cardiovasc Pharmacol 2013; 62(4): 405– 415. doi: 10.1097/ FJC.0b013e3182a094a1.

25. Fogari R, Zoppi A, Maf­fioli P et al. Ef­fect of telmisartan on paroxysmal atrial fibril­lation recur­rence in hypertensive patients with normal or increased left atrial size. Clin Cardiol 2012; 35(6): 359– 364. doi: 10.1002/ clc.21994.

26. Galzerano D, Di Michele S, Paolis­so G et al. A multicentre, randomized study of telmisartan versus carvedilol for prevention of atrial fibril­lation recur­rence in hypertensive patiens. J Renin Angiotensin Aldosterone Syst 2012; 13(4): 496– 503. doi: 10.1177/ 1470320312443909.

27. Zhao D, Wang ZM, Wang LS. Prevention of atrial fibril­lation with renin-angiotensin system inhibitors on es­sential hypertensive patients: a meta-analysis of randomized control­led trials. J Biomed Res 2015; 29(6): 475– 485. doi: 10.7555/ JBR.29.20140149.

28. Schmieder RE, Kjeldsen SE, Julius S et al. Reduced incidence of new-onset atrial fibril­lation with angiotensin II receptor blockade: the VALUE trial. J Hypertens 2008; 26(3): 403– 411. doi: 10.1097/ HJH.0b013e3282f35c67.

29. Qi WW, Liu T, Xu G et al. Upstream therapeutic strategies of Valsartan and Fluvastatin on Hypertensive patients with non-permanent Atrial Fibril­lation (VF-HT-AF): study protocol for a randomized control­led trial. Trials 2015; 16: 336. doi: 10.1186/ s13063-015-0836-5.

30. Alings M, Smit MD, Moes ML et al. Routine versus aggres­sive upstream rhythm control for prevention of early atrial fibril­lation in heart fail­ure: background, aims and design of the RACE 3 study. Neth Heart J 2013; 21(7– 8): 354– 363. doi: 10.1007/ s12471-013-0428-5.

31. Cosio FG, Aliot E, Botto GL et al. Delayed rhythm control of atrial fibril­lation may be a cause of failure to prevent recur­rences: reasons for change to active antiar­rhythmic treatment at the time of the first detected episode. Europace 2008; 10(1): 21– 27. doi: 10.1093/ europace/ eum276.

Labels
Paediatric cardiology Internal medicine Cardiac surgery Cardiology
Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

×